liu.seSearch for publications in DiVA
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Allmän TBE-vaccination ger hälsovinst till rimlig kostnad [Subsidized TBE vaccination appears cost-effective in a life-time perspective]
Karolinska Institute, Sweden.
Karolinska Institute, Sweden.
Linköping University, Department of Medical and Health Sciences, Division of Health Care Analysis. Linköping University, Faculty of Medicine and Health Sciences.
2019 (Swedish)In: Läkartidningen, ISSN 0023-7205, E-ISSN 1652-7518, Vol. 116Article in journal, Editorial material (Refereed) Published
Abstract [en]

Given the setting of Stockholm County, a recently published health-economic analysis shows that the cost per Quality-adjusted life year (QALY) of a free TBE vaccinations program is below generally acceptable cost-effectiveness thresholds in Sweden. A report from the Public Health Agency (PHA), based on similar input data, shows that it is not cost effective to subsidize TBE vaccination in the Stockholm county. The main difference in the two analyses is the time horizon for the analyses; a life-time perspective versus 10-year perspective. Health economics of vaccination strategies should be based on a long time perspective and especially when the disease is more severe in older adults, i.e. TBE. Health-care decision-makers should be aware of the importance of the time horizon for the results when considering these evaluations in prioritization decisions. With a life-time perspective a TBE-vaccination program appears cost-effective.

Abstract [sv]

Beräknat på ett livstidsperspektiv är kostnaden per kvalitetsjusterat levnadsår (QALY) för samhällsfinansierad TBE-vaccination i ett område med TBE-incidens och sjukvårdskostnader motsvarande Stockholms län 28 000–161 000 kronor, beroende på ålder vid vaccinationsstart.

I hälsoekonomiska analyser bör det tydligt framgå vilket tidsperspektiv som använts när vaccination utvärderas, eftersom detta kan vara avgörande för slutsatserna.

Place, publisher, year, edition, pages
Stockholm, Sweden: Sveriges Läkarförbund , 2019. Vol. 116
National Category
Health Care Service and Management, Health Policy and Services and Health Economy
Identifiers
URN: urn:nbn:se:liu:diva-164811PubMedID: 31192427OAI: oai:DiVA.org:liu-164811DiVA, id: diva2:1421076
Available from: 2020-04-01 Created: 2020-04-01 Last updated: 2020-04-08Bibliographically approved

Open Access in DiVA

No full text in DiVA

Other links

PubMedLink to article

Authority records BETA

Henriksson, Martin

Search in DiVA

By author/editor
Henriksson, Martin
By organisation
Division of Health Care AnalysisFaculty of Medicine and Health Sciences
In the same journal
Läkartidningen
Health Care Service and Management, Health Policy and Services and Health Economy

Search outside of DiVA

GoogleGoogle Scholar

pubmed
urn-nbn

Altmetric score

pubmed
urn-nbn
Total: 18 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf